利什曼病

Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8:191-199.

• 摘要

Amato VS, Tuon FF, Bacha HA, et al. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop. 2008;105:1-9.

• 摘要

Musa A, Khalil E, Hailu A, et al. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis. 2012;6:e1674.

• 全文
• 摘要

1.  Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007;7:581-596.

• 摘要

2.  Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873-882, S7-S16.

• 摘要

3.  Killick-Kendrick R. The biology and control of phlebotomine sand flies. Clin Dermatol. 1999;17:279-289.

• 摘要

4.  Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev. 2001;14:659-688.

• 全文
• 摘要

5.  Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8:191-199.

• 摘要

6.  Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3:87-98.

• 摘要

7.  Cabello I, Caraballo A, Millan Y. Leishmaniasis in the genital area. Rev Inst Med Trop Sao Paulo. 2002;44:105-107.

• 全文
• 摘要

8.  Martinez-Garcia F, Regadera J, Mayer R, et al. Protozoan infections in the male genital tract. J Urol. 1996;156:340-349.

• 摘要

9.  Wortmann GW, Aronson NE, Miller RS, et al. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis. 2000;31:199-201.

• 全文
• 摘要

10.  Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol. 2002;97(suppl 1):107-114.

• 摘要

11.  Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80:859-876.

• 摘要

12.  Amato VS, Tuon FF, Bacha HA, et al. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop. 2008;105:1-9.

• 摘要

13.  GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1603-1658.

• 全文
• 摘要

14.  World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2010:xii-xiii;1-186;back cover.

• 摘要

15.  Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.

• 全文
• 摘要

16.  Pigott DM, Bhatt S, Golding N, et al. Global distribution maps of the leishmaniases. Elife. 2014:3.

• 全文
• 摘要

17.  Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21:334-359.

• 全文
• 摘要

18.  Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111-126.

• 全文
• 摘要

19.  Wright NA, Davis LE, Aftergut KS, et al. Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. J Am Acad Dermatol. 2008;58:650-652.

• 摘要

20.  Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004;53:158-166.

• 全文
• 摘要

21.  Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM. 2004;97:781-788.

• 摘要

22.  Weina PJ, Neafie RC, Wortmann G, et al. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis. 2004;39:1674-1680.

• 全文
• 摘要

23.  Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006;22:552-557.

• 摘要

24.  Myles O, Wortmann GW, Cummings JF, et al. Visceral leishmaniasis: clinical observations in 4 US army soldiers deployed to Afghanistan or Iraq, 2002-2004. Arch Intern Med. 2007;167:1899-1901.

• 摘要

25.  Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002;35:261-267.

• 全文
• 摘要

26.  Duprey ZH, Steurer FJ, Rooney JA, et al. Canine visceral leishmaniasis, United States and Canada, 2000-2003. Emerg Infect Dis. 2006;12:440-446.

• 全文
• 摘要

27.  Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv Parasitol. 2005;59:1-75.

• 摘要

28.  Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun. 2002;70:6919-6925.

• 全文
• 摘要

29.  Rogers ME, Ilg T, Nikolaev AV, et al. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature. 2004;430:463-467.

• 摘要

30.  Vannier-Santos MA, Martiny A, de Souza W. Cell biology of Leishmania spp.: invading and evading. Curr Pharm Des. 2002;8:297-318.

• 摘要

31.  Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2000;2:1765-1773.

• 摘要

32.  Belkaid Y, Valenzuela JG, Kamhawi S, et al. Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: an adaptive response induced by the fly? Proc Natl Acad Sci U S A. 2000;97:6704-6709.

• 全文
• 摘要

33.  Warburg A, Saraiva E, Lanzaro GC, et al. Saliva of Lutzomyia longipalpis sibling species differs in its composition and capacity to enhance leishmaniasis. Philos Trans R Soc Lond B. 1994;345:223-230.

• 摘要

34.  Basu MK, Ray M. Macrophage and Leishmania: an unacceptable coexistence. Crit Rev Microbiol. 2005;31:145-154.

• 摘要

35.  Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis. 1987;156:1030-1033.

• 摘要

36.  Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS. 1999;13:459-465.

• 摘要

37.  Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis. 2005;11:655-662.

• 全文
• 摘要

38.  Brooker S, Mohammed N, Adil K, et al. Leishmaniasis in refugee and local Pakistani populations. Emerg Infect Dis. 2004;10:1681-1684.

• 全文
• 摘要

39.  Kolaczinski JH, Reithinger R, Worku DT, et al. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol. 2008;37:344-352.

• 摘要

40.  Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg. 2000;63:184-188.

• 全文
• 摘要

41.  Kopterides P, Mourtzoukou EG, Skopelitis E, et al. Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg. 2007;101:1181-1189.

• 摘要

42.  Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011;11:322-325.

• 摘要

43.  Romero GA, Boelaert M. Control of visceral leishmaniasis in Latin America: a systematic review. PLoS Negl Trop Dis. 2010;4:e584.

• 全文
• 摘要

44.  González U, Pinart M, Sinclair D, et al, Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev. 2015;(8):CD008736.

• 全文
• 摘要

45.  Picado A, Singh SP, Rijal S, et al. Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ. 2010;341:c6760.

• 全文
• 摘要

46.  Chowdhury R, Dotson E, Blackstock AJ, et al. Comparison of insecticide-treated nets and indoor residual spraying to control the vector of visceral leishmaniasis in Mymensingh District, Bangladesh. Am J Trop Med Hyg. 2011;84:662-667.

• 摘要

47.  Costa CH. How effective is dog culling in controlling zoonotic visceral leishmaniasis? A critical evaluation of the science, politics and ethics behind this public health policy. Rev Soc Bras Med Trop. 2011;44:232-242.

• 全文
• 摘要

48.  Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: progress and problems. Parasitology. 2006;133(suppl):S87-S112.

• 摘要

49.  Boelaert M, Bhattacharya S, Chappuis F, et al. Evaluation of rapid diagnostic tests: visceral leishmaniasis. Nat Rev Microbiol. 2007;5(suppl):S30-S39.

50.  Escobar MA, Martinez F, Scott Smith D, et al. American cutaneous and mucocutaneous leishmaniasis (tegumentary): a diagnostic challenge. Trop Doct. 1992;22(suppl 1):69-78;63-64.

• 摘要

51.  Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007;45:21-25.

• 全文
• 摘要

52.  Cota GF, de Sousa MR, Demarqui FN, et al. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis. 2012;6:e1665.

• 全文
• 摘要

53.  Cruz I, Chicharro C, Nieto J, et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol. 2006;44:2343-2347.

• 全文
• 摘要

54.  Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1990;84:673-675.

• 摘要

55.  De Almeida Silva L, Romero HD, Prata A, et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg. 2006;75:739-743.

• 全文
• 摘要

56.  Boelaert M, Rijal S, Regmi S, et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg. 2004;70:72-77.

• 全文
• 摘要

57.  Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis. 2000;31:1093-1095.

• 全文
• 摘要

58.  Weigle KA, de Davalos M, Heredia P, et al. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg. 1987;36:489-496.

• 摘要

59.  Kager PA, Rees PH. Splenic aspiration. Review of the literature. Trop Geogr Med. 1983;35:111-124.

• 摘要

60.  Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg. 1992;86:505-507.

• 摘要

61.  da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg. 2005;72:811-814.

• 摘要

62.  Schuster FL, Sullivan JJ. Cultivation of clinically significant hemoflagellates. Clin Microbiol Rev. 2002;15:374-389.

• 全文
• 摘要

63.  Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ. 2006;333:723.

• 全文
• 摘要

64.  Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev. 2014;(6):CD009135.

• 全文
• 摘要

65.  Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg. 2008;102:32-40.

• 摘要

66.  de Assis TS, Braga AS, Pedras MJ, et al. Multi-centric prospective evaluation of rk39 rapid test and direct agglutination test for the diagnosis of visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2011;105:81-85.

• 摘要

67.  Harith AE, Kolk AH, Kager PA, et al. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA. Trans R Soc Trop Med Hyg. 1987;81:603-606.

• 摘要

68.  Iqbal J, Hira PR, Saroj G, et al. Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J Clin Microbiol. 2002;40:475-479.

• 全文
• 摘要

69.  Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol. 2002;9:951-958.

• 全文
• 摘要

70.  Maurya R, Singh RK, Kumar B, et al. Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure. J Clin Microbiol. 2005;43:3038-3041.

• 全文
• 摘要

71.  Marty P, Lelièvre A, Quaranta JF, et al. Detection by Western blot of four antigens characterizing acute clinical leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg. 1995;89:690-691.

• 摘要

72.  Singh RK. Hyperreactive malarial splenomegaly in expatriates. Travel Med Infect Dis. 2007;5:24-29.

• 摘要

73.  World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.

74.  Gryseels B, Polman K, Clerinx J, et al. Human schistosomiasis. Lancet. 2006;368:1106-1118.

• 摘要

75.  Schaefer KU, Kurtzhals JA, Gachihi GS, et al. A prospective sero-epidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. Trans R Soc Trop Med Hyg. 1995;89:471-475.

• 摘要

76.  Davies CR, Llanos-Cuentas EA, Pyke SD, et al. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect. 1995;114:297-318.

• 摘要

77.  Cardo LJ. Leishmania: risk to the blood supply. Transfusion. 2006;46:1641-1645.

• 摘要

78.  Thakur CP, Sinha GP, Pandey AK, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol. 1998;92:561-569.

• 摘要

79.  Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ. 2005;83:394-395.

• 全文
• 摘要

80.  Berman JD. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999;28:49-51.

• 摘要

81.  Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 1998;76:25-32.

• 摘要

82.  Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006;43:917-924.

• 全文
• 摘要

83.  Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362:504-512.

• 摘要

84.  Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis. 2005;5:763-774.

• 摘要

85.  Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004;38:377-383.

• 全文
• 摘要

86.  Sundar S, Mehta H, Chhabra A, et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis. 2006;42:608-613.

• 全文
• 摘要

87.  Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother. 2006;58:811-815.

• 全文
• 摘要

88.  Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother. 2005;55:229-233.

• 全文
• 摘要

89.  Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des. 2002;8:319-342.

• 摘要

90.  Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007;77:266-274.

• 全文
• 摘要

91.  Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica. 2011;118:87-96.

• 摘要

92.  González U, Pinart M, Reveiz L, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev. 2008;(4):CD005067.

• 全文
• 摘要

93.  González U, Pinart M, Rengifo-Pardo M, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009;(2):CD004834.

• 全文
• 摘要

94.  Nonata R, Sampaio R, Marsden PD. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Trans R Soc Trop Med Hyg. 1997;91:77.

• 摘要

95.  Amato VS, Rabello A, Rotondo-Silva A, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 2004;92:127-132.

• 摘要

96.  Roussel M, Nacher M, Fremont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2006;100:307-314.

• 摘要

97.  Lai A Fat EJ, Vrede MA, Soetosenojo RM, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol. 2002;41:796-800.

• 摘要

98.  Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2008;78:210-211.

• 摘要

99.  Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis. 2005;40:1148-1155.

• 全文
• 摘要

100.  Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg. 1990;42:43-50.

• 摘要

101.  Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, et al. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am J Trop Med Hyg. 1997;57:309-312.

• 摘要

102.  Bumb RA, Prasad N, Khandelwal K, et al. Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India. Br J Dermatol. 2013;168:1114-1119.

• 摘要

103.  Lawn SD, Armstrong M, Chilton D, et al. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg. 2006;100:264-269.

• 摘要

104.  Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis. 1998;27:1457-1764.

• 摘要

105.  Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007;44:350-356.

• 全文
• 摘要

106.  Osman OF, Oskam L, Zijlstra EE, et al. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment. Trans R Soc Trop Med Hyg. 1998;92:397-400.

• 摘要

107.  World Health Organization. WHO Techical Report Series: control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva: World Health Organization; 22-26 March 2010.

• 全文

108.  Musa A, Khalil E, Hailu A, et al. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis. 2012;6:e1674.

• 全文
• 摘要

109.  Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377:477-486.

• 摘要

110.  Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs. 2008;17:787-794.

• 摘要

111.  Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health. 2003;8:733-739.

• 全文
• 摘要

112.  Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol. 2003;97(suppl 1):135-142.

• 摘要

113.  Lopez-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol. 2003;97(suppl 1):143-147.

• 摘要

114.  Pasquau F, Ena J, Sanchez R, et al. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur J Clin Microbiol Infect Dis. 2005;24:411-418.

• 摘要

115.  Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect. 1996;32:133-137.

• 摘要

116.  Laguna F, Torre-Cisneros J, Moreno V, et al. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:711-712.

• 摘要

117.  Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006;43:357-364.

• 全文
• 摘要

118.  Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS. 1999;13:1063-1069.

• 摘要

119.  Delgado J, Macías J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg. 1999;61:766-769.

• 全文
• 摘要

120.  Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health. 2001;6:849-854.

• 全文
• 摘要

121.  Musa AM, Khalil EA, Mahgoub FA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol. 2005;99:563-569.

• 摘要

122.  Palacios R, Osorio LE, Grajalew LF, et al. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg. 2001;64:187-193.

• 全文
• 摘要

123.  Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis. 2001;33:e57-e61.

• 全文
• 摘要

124.  Soto J, Arana BA, Toledo J, et al. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis. 2004;38:1266-1272.

• 全文
• 摘要

125.  Vélez I, López L, Sánchez X, et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg. 2010;83:351-356.

• 全文
• 摘要

126.  Franke ED, Llanos-Cuentas A, Echevarria J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg. 1994;51:77-82.

• 摘要

127.  Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000;31:1104-1107.

• 全文
• 摘要

128.  Thakur CP, Singh RK, Hassan SM, et al. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg. 1999;93:319-323.

• 摘要

129.  Sundar S, Chakravarty J, Rai VK, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis. 2007;45:556-561.

• 全文
• 摘要

130.  Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg. 2003;97:350-354.

• 摘要

131.  Thakur CP, Narain S, Kumar N, et al. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol. 1997;91:611-616.

• 摘要

132.  Veeken H, Ritmeijer K, Seaman J, et al. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health. 2000;5:312-317.

• 全文
• 摘要

133.  Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356:2571-2581.

• 全文
• 摘要

134.  Hailu A, Musa A, Wasunna M, et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis. 2010;4:e709.

• 全文
• 摘要

135.  Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis. 2007;196:591-598.

• 全文
• 摘要

136.  Sundar S, Kumar K, Chakravarty J, et al. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg. 2006;100:698-700.

• 摘要

137.  Herwaldt BL. Miltefosine - the long-awaited therapy for visceral leishmaniasis? N Engl J Med. 1999;341:1840-1842.

• 摘要

138.  Ramesh V, Singh R, Salotra P. Short communication: post-kala-azar dermal leishmaniasis - an appraisal. Trop Med Int Health. 2007;12:848-851.

• 全文
• 摘要

139.  Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013;368:524-532.

• 摘要

140.  Sosa N, Capitán Z, Nieto J, et al. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg. 2013;89:557-563.

• 全文
• 摘要

141.  Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990;89:147-155.

• 摘要

142.  Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pensostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatamala. J Infect Dis. 1992;165:528-534.

• 摘要

143.  Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002;346:891-895.

• 全文
• 摘要

144.  Mueller Y, Nguimfack A, Cavailler P, et al. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol. 2008;102:11-19.

• 摘要

145.  Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis. 2004;38:612-619.

• 全文
• 摘要

146.  Melaku Y, Collin SM, Keus K, et al. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg. 2007;77:89-94.

• 全文
• 摘要

147.  Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011;5:e1153.

• 全文
• 摘要